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Abstract. Aims: Anti-Apolipoprotein A-1 autoantibodies (anti-ApoA-1 IgG) promote atherogenesis 
via innate immune receptors, and may impair cellular cholesterol homeostasis (CH). We explored 
the presence of anti-ApoA-1 IgG in children (5–15 years old) with or without familial 
hypercholesterolemia (FH), analyzing their association with lipid profiles, and studied their in vitro 
effects on foam cell formation, gene regulation, and their functional impact on cholesterol passive 
diffusion (PD). Methods: Anti-ApoA-1 IgG and lipid profiles were measured on 29 FH and 25 
healthy children. The impact of anti-ApoA-1 IgG on key CH regulators (SREBP2, HMGCR, LDL-R, 
ABCA1, and miR-33a) and foam cell formation detected by Oil Red O staining were assessed using 
human monocyte-derived macrophages. PD experiments were performed using a validated THP-1 
macrophage model. Results: Prevalence of high anti-ApoA-1 IgG levels (seropositivity) was about 
38% in both study groups. FH children seropositive for anti-ApoA-1 IgG had significant lower total 
cholesterol LDL and miR-33a levels than those who were seronegative. On macrophages, anti-
ApoA-1 IgG induced foam cell formation in a toll-like receptor (TLR) 2/4-dependent manner, 
accompanied by NF-kB- and AP1-dependent increases of SREBP-2, LDL-R, and HMGCR. Despite 
increased ABCA1 and decreased mature miR-33a expression, the increased ACAT activity 
decreased membrane free cholesterol, functionally culminating to PD inhibition. Conclusions: Anti-
ApoA-1 IgG seropositivity is frequent in children, unrelated to FH, and paradoxically associated 
with a favorable lipid profile. In vitro, anti-ApoA-1 IgG induced foam cell formation through a 
complex interplay between innate immune receptors and key cholesterol homeostasis regulators, 
functionally impairing the PD cholesterol efflux capacity of macrophages. 
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1. Introduction 
Humoral autoimmunity has recently been shown to represent a dual mediator of atherogenesis 
and cardiovascular diseases (CVD) by modulating three main pathways, including inflammation, 
coagulation, and foam cell formation [1,2]. Among autoantibodies of interest in CVD, the interest in 
antibodies against apolipoprotein A-1 (anti-ApoA-1 IgG) appears to be gaining momentum. Indeed, 
three recent studies derived from a large multicenter general population cohort demonstrated that 
anti-ApoA-1 IgGs were an independent cardiovascular (CV) risk factor predictive of poor prognosis 
[3–5] similarly to what had been reported previously and more recently in high CV risk populations 
[6–11]. In parallel, translational studies pointed to these autoantibodies as mediators of atherogenesis, 
promoting atherosclerosis, myocardial necrosis, and mice death through toll-like receptors (TLR) 2,4 
and CD14 signaling [12–14]. Interestingly, inverse associations were regularly noted between anti-
ApoA-1 IgG, total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) 
levels [3,13,15,16], potentially suggesting that these antibodies could also interfere with cholesterol 
metabolism in addition to their established pro-inflammatory and pro-thrombotic properties 
[13,14,17]. Such a hypothesis has been further supported by two recent observations. The first showed 
that antibodies directed against the c-terminal part of ApoA-1 in type 2 diabetes were associated with 
decreased cholesterol efflux capacity (CEC) of fibroblasts [18]. The second reported that anti-ApoA-
1 IgG levels were inversely associated with PD- and positively associated with ABCA1-CEC in 
healthy obese subjects, with the capacity, to enhance ABCA1-CEC in vitro while repressing PD-CEC, 
leading to foam cell formation [19], the hallmark of atherosclerosis [20]. Nevertheless, the exact 
molecular mechanisms underlying these drastic cellular phenotype modifications induced by anti-
apoA-1 IgG are still elusive, and likely to imply major changes in the gene and protein expression 
levels of key regulators of cellular cholesterol homeostasis; whether such effect could be reproduced 
in human macrophages is currently unknown [20–23]. 
Among these, 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) and low-density 
lipoprotein receptor (LDL-R) are known as key cholesterol homeostasis regulatory elements leading 
to the developments of statins, the most efficient and commonly used pharmacological molecules 
available to prevent atherosclerosis-related complications [21]. HMGCR and LDLR are controlled by 
the sterol regulatory element binding protein 2 (SREBP2) encoded by SREBF2 gene, which contains 
microRNAs 33a (miR-33a) in its intronic sequence and reduces cholesterol efflux via repression of the 
adenosine triphosphate (ATP)-binding cassette transporter A1 (ABCA1), impairing HDL biogenesis 
[22,23]. Upon SREBF2 gene activation, both LDLR and HMGCR are upregulated by SREBP2, 
enhancing LDL uptake and increasing intracellular cholesterol synthesis. In response to SREBF2 gene 
transcription, miR-33a expression will increase, inhibiting ABCA-1 cholesterol efflux [22,23]. 
Therefore, miR-33a and SREBP2 act synergistically to efficiently increase cellular cholesterol levels 
by inhibiting cellular cholesterol efflux and increasing lipid uptake and intracellular synthesis, 
respectively. While previous studies suggested that miR-33 may represent therapeutic target for the 
treatment of cardiovascular disease [24,25], a recent work showed that miR-33 deletion in mice results 
in dyslipidemia, obesity, and insulin resistance [26], assigning a role for miR-33 that is much more 
complex than what has been considered so far. Such complexity has also been illustrated in humans 
by the fact that miR-33 levels are surprisingly elevated in pediatric patients affected by familial 
hypercholesterolemia (FH) [27]. 
Since foam cells can be generated by the uncontrolled uptake of unmodified LDL via LDL-R 
[28,29], any factor influencing LDLR, HMGCR, or miR-33a expression will efficiently modulate lipid 
uptake, cellular cholesterol synthesis, and cholesterol efflux, and therefore affect atherogenesis. 
Taken together, these observations suggest that anti-ApoA-1 IgG may reorient the lipids from 
the plasmatic compartment toward the intracellular lipid pools, potentially explaining the 
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paradoxical associations frequently retrieved between anti-apoA-1 IgG and lipid profile despite an 
increased CV risk. If so, such a hypothesis would imply modulation of key regulators of cellular 
cholesterol homeostasis and foam cell formation, including miR-33. 
Therefore, in this translational study, we explored the associations between anti-ApoA-1 IgG, lipid 
profile, and miR-33a levels in FH children as an extreme and optimal human dyslipidemia phenotype to 
perform such explorations and compared whether such associations could be retrieved in age- and 
gender-matched controls. Fueled by these clinical observations, we then dissected the in vitro mechanisms 
by which anti-ApoA-1 IgG could lead to foam cell formation. Our results showed that associations 
between anti-ApoA-1 IgG, lipid profile, and miR-33 levels were only retrieved in FH children. 
Furthermore, our in vitro studies using human macrophages provided the first molecular insights on how 
these antibodies could act as novel endogenous cholesterol homeostasis disruptors. 
2. Experimental Section 
2.1. Patients 
In this study, we considered 29 children (14 males and 15 females) aged 5–15 affected by FH and 
referred to the Center of Clinical Lipid Research, Department of Pediatrics, Sapienza University of 
Rome [27]. Children were classified as FH on the basis of the presence of a first-degree relative with 
hypercholesterolemia (total cholesterol (TC) >95th age and sex-specific percentile) according to the 
MEDPED criteria [30]. In the same center, a control group of 25 healthy children (11 males, 14 female) 
was recruited with a BMI (body mass index) appropriate for their age and gender, as matched for age 
with the FH group. 
Exclusion criteria consisted of acute or chronic disease or infection (connective tissue disease, 
hypothyroidism, renal disease, malignancy, clinical evidence of CVD, diabetes mellitus, hypertension 
or metabolic syndrome), autoimmune disease, or the use of medication potentially affecting growth 
and development, associated with a history of alcohol consumption and smoking (when 
appropriate), immunosuppressive drugs, non-steroidal, anti-inflammatory, lipid-lowering drugs, 
and/or vitamin supplements. 
At first visit, anthropometric data were measured (body weight and waist, hip, and arm 
circumferences). Weight was measured using an electronic scale (Soehnle, Murrhardt, Germany) and 
standing height was measured with the Harpenden Stadiometer (Holtain, Crymych, UK). Systolic 
and diastolic blood pressure was measured using a random zero sphygmomanometer (Hawksley & 
Sons Ltd., Lancing, UK); the mean of three measurements was used in the analysis. BMI was 
calculated as weight/height2 (kg/m2). 
Informed written consent was obtained from all the participants. The study was in conformity 
with the ethical guidelines of the Declaration of Helsinki, and was reviewed and cleared by the 
Ethical Committee of Sapienza University of Rome. 
2.2. Plasma Samples and Blood Analyses 
Venous blood samples (10 mL) were collected in EDTA-containing tubes from 12 h fasted 
subjects. Blood was then centrifuged (1200g for 10 min at 4 °C). Supernatant was then collected and 
centrifuged (2,000g for 10 min at 4 °C). Plasma samples were stored at −80 °C and were thawed on 
ice before use. Plasma concentrations of lipoprotein and apolipoproteins were determined as 
previously described [27]. LDL cholesterol was calculated using Friedewald’s equation. 
2.3. Assessment of Anti-ApoA-1 IgG Levels 
Anti-ApoA-1 IgG were measured as previously described [7,9,13,14,17]. Briefly, MaxiSorp plates 
(NuncTM, city, Roskilde, Denmark) were coated with purified, human-derived delipidated 
apolipoprotein A-1 (20 μg/mL; 50 μL/well) for 1 h at 37 °C. After being washed, all wells were blocked 
for 1 h with 2% bovine serum albumin (BSA) in a phosphate-buffered solution (PBS) at 37 °C. FH 
samples were also added to a non-coated well in order to assess individual non-specific binding. 
After six washing cycles, 50 μL/well of the alkaline phosphatase-conjugated anti-human IgG was 
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added (Sigma-Aldrich, St Louis, MO, USA), it was diluted at 1:1000 in a PBS/BSA 2% solution, and 
this was added and incubated for 1 h at 37 °C. After washing six more times, phosphatase substrate 
p-nitrophanylphosphate disodium (Sigma-Aldrich) dissolved in a diethanolamine buffer (pH 9.8) 
was added and incubated for 30 min at 37 °C. Optical density (OD) was determined at 405 nm 
(Filtermax 3, Molecular DevicesTM, San Jose, CA, USA). and each sample was tested in duplicate. 
Corresponding non-specific binding was subtracted from mean OD for each sample. The specificity 
of detection was assessed using conventional saturation tests by Western blot analysis. 
As previously described, elevated levels of anti-ApoA-1 IgG (seropositivity) were defined by an 
OD cutoff of OD > 0.64 corresponding to the 97.5th percentile of a reference population. In order to 
limit the impact of interassay variation, we further calculated an index consisting of the ratio between 
sample net absorbance and the positive control net absorbance × 100. The index value corresponding 
to the 97.5th percentile of the normal distribution was 37. Accordingly, to be considered as positive 
(presenting elevated anti-apoA-1 IgG levels), samples had to display both an absorbance value of OD 
> 0.64 and an index value ≥37%. [7,9,13,14,17]. 
2.4. Reagents 
RPMI-1640 medium, fetal bovine serum (FBS), PBS free of Ca2+ and Mg2+, L-glutamine, penicillin, 
and streptomycin were obtained from Gibco BRL-Life Technologies (Rockville, MD, USA). 
Interferon-gamma (IFN-γ) was from Roche (Mannheim, Germany). 
Affinity purified goat polyclonal anti-human ApoA-1 IgG (ref. 11AG2) was obtained from 
Academy Bio-Medical Company (Houston, TX, USA) and goat control IgG were from Meridian Life 
Science (ref. A66200H) (Saco, ME, USA). Ultrapure lipopolysaccharide (LPS) from Escherichia coli was 
purchased from Alexis Enzo Life Sciences (Lausen, Switzerland). Blocking anti-human TLR4 (clone 
HTA 125) antibody, anti-human TLR2 antibody (clone TL2.1), and matched isotype control 
antibodies were from Biolegend (San Diego, CA, USA). Blocking anti-human TLR2 (clone TL2.5) and 
blocking anti-human CD14 antibodies were from InvivoGen (San Diego, CA, USA). SP600125 (c-Jun 
N-terminal kinase (JNK) inhibitor and BAY11-7082 (IkB-α inhibitor) were from InvivoGen. San 
Diego, CA, USA) 
2.5. Human Monocyte-Derived Macrophage Preparation 
Human monocytes were isolated from buffy coats obtained from healthy donors in the Geneva 
Hospital Blood Transfusion Center (Geneva, Switzerland) and differentiated into macrophages by 24 
hours incubation with IFN-γ (500 U/mL) in a complete RPMI-1640 culture medium (10% heat-inactivated 
FCS, 50 μg/mL streptomycin, 50 U/mL penicillin, 2 mM L-glutamine) as previously described [14,17]. 
Macrophage preparation consisted of >90% CD68+ cells as assessed by flow cytometry. 
When indicated, anti-TLR4, anti-TLR2 (TL2.5/2.1), and anti-CD14 blocking antibodies, as well as 
isotype-matched control mAb (10 μg/mL) and specific pharmacological inhibitors, were added 30 
min before stimulation with IgG [14,17]. 
2.6. Protein Purification and Western Blot Analysis 
Macrophages (2 × 106) were lysed at 4 °C for 20 min with radioimmunoprecipitation assay (RIPA) 
lysis buffer with added protease inhibitors (Complete tablets, mini, Roche diagnostics, Mannheim, 
Germany) and phosphatase inhibitors (Halt Protease and Phosphatase Inhibitor Cocktail, Thermo 
Scientific, Waltham, MA, USA) and then samples were centrifuged at 14,000 rpm at 4 °C for 15 min. 
Protein concentration was determined by Bradford protein assay (Biorad, Hercules, CA, USA). To 
increase protein concentration, samples were loaded onto Amicon Ultra-0.5 centrifugal filter devices 
3K (Merck Millipore, Darmstadt, Germany) following the manufacturer’s instructions. Forty 
micrograms of total protein extract were resolved by 8% or 10% polyacrylamide gel electrophoresis 
under reducing conditions, and transferred to a polyvinylidene difluoride (PVDF) membrane 
(Immobilon, Millipore IPVH 00010). Membranes were incubated with the following antibodies: anti-
SREBP2 (rabbit polyclonal, ref. 10007663, Cayman chemical, Ann Arbor, MI, Stati Uniti), anti-LDL 
J. Clin. Med. 2019, 8, 2035 5 of 20 
 
Receptor (rabbit monoclonal, ref. ab52818, Abcam, Cambridge, UK), anti-HMGCR (rabbit 
monoclonal, ref. ab174830, Abcam), anti-SCAP (Rabbit polyclonal, ref. ab125186 Abcam), anti-
ABCA1 (rabbit polyclonal, ref. NB400-105, Novus Biologicals, Centennial, CO, USA), anti-β-actin 
(mouse monoclonal, ref. ab8226, Abcam). Horseradish peroxidase-conjugated antisera from Dako 
(Glostrup, Denmark), were used to reveal primary antibody binding, with detection by BM 
Chemiluminescence Blotting Substrate (POD) from Roche Diagnostics (Mannheim, Germany). 
Relative protein levels were measured using densitometric analysis with ImageJ software (1.48v, Java 
1.5.0_20, 64-bit). Results are expressed in arbitrary units. 
2.7. Lipid Uptake by Oil Red O Staining 
Monocytes (3 × 105) were plated onto Lab-Tek chamber slide system (Nunc, Roskilde, Denmark) 
and IFN-γ (500 U/mL) was added to RPMI supplemented with 10% FCS for 24 h at 37 °C. After that 
time, cells were washed once with PBS and exposed, or not, for 24 h to 20 μg/mL LDL from Academy 
Bio-Medical Company (Houston, TX, USA). One hour before adding LDL, cells were incubated with 
40 μg/mL of goat polyclonal anti-human apolipoprotein A-1 or control IgG, shown to be the optimal 
dose to elicit a pro-inflammatory response [7,9,13,14,17]. Cells were examined for lipid inclusion by 
Oil Red O staining. Briefly, cells were incubated with 10% formalin (Sigma-Aldrich, St Louis, MO, 
USA) for 30 min at room temperature, incubated with Oil Red O solution (Sigma- Aldrich, St Louis, 
MO, USA) for 15 min, and cells were then counterstained with hematoxylin (Sigma- Aldrich, St Louis, 
MO, USA). Aquatex (Merck Millipore, Darmstadt, Germany) was used as mounting media. Images 
were acquired with a microscope Zeiss Axioskop 2 plus. We used a 40× objective (Plan-Neofluar 40× 
/0.75 Ph2) for all images. The images were collected using the AxioVision 4.8.1.0 softwares (Zeiss, 
Oberkochen, Germania). Quantification of the lipid content (Oil Red O staining) per cell, identified 
by hematoxylin blue nuclear staining, was performed using Definiens Developer XD2 (Cambridge, 
MA USA). Results are expressed as mean granule area in arbitrary units. 
2.8. RNA Extraction 
Macrophage cells (1 × 106) were subjected to RNA extraction using a total RNA purification 
RNeasy Micro kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. RNA from 
plasma (200 μL) was extracted using a Total RNA Purification Plus kit (Norgen Biotek, Thorold, ON, 
Canada) and RNA from macrophage supernatant (200 μL) was extracted using TRIzol LS (Ambion, 
Life-Technologies, Austin, TX, USA) as an internal control, with 10 fmol cel-miR-39a (Qiagen, Hilden, 
Germany) spiked into each plasma and supernatant sample after adding lysis buffer or TRIzol LS. 
We then followed the manufacturer’s protocol for RNA extraction. RNA was quantified using 
NanoDrop 2000 software (NanoDrop Products, Thermo Fisher Scientific, Wilmington, DE, USA.). 
2.9. miRNA Quantitative PCR 
miRNA quantification was done using a TaqMan®MicroRNA Reverse Trancription Kit (Applied 
Biosystems) for reverse transcription reactions, according to the manufacturer’s instructions. TaqMan 
Universal PCR master mix (Life Technologies, Carlsbad, CA, USA) was used to quantify miRNA 
levels in plasma, macrophage cells, and in the supernatant counterpart with a 7900HT SDS Fast 
System instrument (Applied Biosystems, Foster City, CA, USA). Primers for miR-33a, cel-miR-39a 
were obtained from Applied Biosystems (Foster City, CA, USA). miR-33a level in plasma and in cell 
supernatant were normalized to the spiked cel-miR-39a whereas miR-33a expression levels in each 
sample from macrophage cells were normalized to RNU6B, miR-16, Z30 controls (Applied 
Biosystems, Foster City, CA, USA). geNorm was used to determine the most stable genes from the 
set of control tested genes since geNorm calculates the gene expression stability measure (M value) 
for a control gene as the average pairwise variation for that gene with all other tested control genes 
[31]. Data were analyzed with the 7900HT SDS Software v2.3 (Applied Biosystems, Foster City, CA, 
USA). Relative expressions of miR-33a were calculated using the comparative threshold cycle values 
(CT) method (2−ΔΔCt) [32]. 
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2.10. Quantitative PCR 
For mRNA quantification, cDNA was synthesized using the High Capacity RNA to cDNA kit 
(Life Technologies, Carlsbad, CA, USA). Quantitative re al-time PCR was performed in duplicate 
using TaqMan Universal Master mix II, no UNG on the StepOne Plus Real-Time PCR System (Thermo 
Fisher Scientific, Waltham, MA, USA). The mRNA levels were normalized to Gapdh 
(hs99999905_m1) as a housekeeping gene. The following primers were used: pri-miR-33a 
(hs03293451), Abca1 (hs01059137_m1), and Srebf-2 (hs01081784_m1). All primers were obtained from 
(Applied Biosystems, Foster City, CA, USA). Data were analyzed with the 7900HT SDS Software v2.3 
(Applied Biosystems, Foster City, CA, USA). Relative expression of mRNA was calculated using the 
comparative threshold cycles values (CT) method (2−ΔΔCt) [32]. 
2.11. Anti-ApoA-1 IgG Modulation of Membrane Free Cholesterol. Assay of Cholesterol Oxidase 
Cholesterol oxidase treatment was essentially as previously described [33]. Briefly, cells were 
labeled with 3 μCi/mL [3 H] cholesterol. Cholesterol oxidase (1 U/mL) was added, and cells were 
incubated for 4 hours. Lipid was extracted with isopropanol, and radioactive cholesterol and 
cholestenone were separated using thin-layer chromatography and quantified. 
2.12. ACAT Activity Assessment 
Cholesterol esterification was evaluated as the incorporation of radioactivity into cellular 
cholesteryl esters after addition of [14C]-oleate-albumin complex [34]. At the end of incubation, cells 
were washed with PBS and lipids were extracted with hexane/isopropanol (3:2). The extracted lipids 
were separated by TLC (isooctane/diethyl ether/acetic acid, 75:25:2 (v/v/v)). Cholesterol radioactivity 
in the spots was determined by liquid scintillation counting. 
2.13. Measurement of Free Cholesterol Content in Cell Supernatant 
Free cholesterol in supernatant was measured using the fluorometric method using the 
Cholesterol Quantitation Assay Kit by Abcam (ab65359, Cambridge, UK) following the 
manufacturer’s instruction. The experiments were conducted without ACAT inhibitors. 
2.14. Passive Diffusion Analysis 
We used a validated model of THP-1 monocytes cultured in RPMI 1640 medium supplemented 
with 10% FBS at 37 °C in 5% CO2 [35]. To perform the experiments for passive diffusion, cells were 
seeded in 24-well plates at a density of 5 × 105 cells/well in the presence of 100 ng/mL PMA for 72 h 
to allow differentiation into macrophages. Cells were labeled with (1,2-3H)-cholesterol in the 
presence of an ACAT inhibitor (2 μg/mL, Sandoz 58035 by Sandoz, Holzkirchen, Germany) for 24 h. 
In order to measure passive diffusion, the key cholesterol efflux regulator in non-dyslipidemic 
macrophages [36], the experiment was performed in the absence of 10% whole serum, but cells were 
supplemented with 0.2% albumin to avoid any active ABCA1- or ABCG1-mediated cholesterol efflux. 
Cholesterol measurement was expressed as a percentage of the radioactivity released to the medium 
in 4 h over the total radioactivity incorporated by cells. Control samples were run to confirm the 
responsiveness of cells. Background efflux, evaluated in the absence of acceptors, was subtracted 
from each samples value. 
2.15. Statistics 
Continuous variables were expressed as median (interquartile range (IQR)) and comparisons 
between two groups were performed using a non-parametric Mann–Whitney U test, unless stated 
otherwise. Correlation analysis was carried out using a Spearman test. Analyses were performed 
with Statistica package (version13.5.0.17, TIBCO Software inc., Palo Alto, CA, USA). Statistical 
significance was defined at p < 0.05. For the in vitro results, statistical analysis was performed using 
J. Clin. Med. 2019, 8, 2035 7 of 20 
 
the parametric unpaired Student’s t-test using GraphPad Prism (version 7.0., GraphPad SoftwareSan 
Diego, CA, USA).  Statistical significance was defined as p < 0.05. 
3. Results 
3.1. Anti-ApoA-1 IgG Associations with Lipid Profile in FH Children 
Baseline, clinical, and biological characteristics of FH and healthy children are described in Table 
1. As expected, FH children had higher levels of total cholesterol, LDL cholesterol, apoB particles, 
HDL cholesterol, and miR-33a than their age-matched controls. No other differences in baseline 
clinical characteristics were observed between these two groups. Median anti-ApoA-1 IgG were 
similar in these two groups and a similar prevalence of high anti-ApoA-1 IgG levels was retrieved in 
both groups (38.8% and 37.9%, respectively). 
In FH children, there were no significant differences between anti-ApoA-1 IgG positive and anti-
ApoA-1 IgG negative children in terms of age, gender, and overweight-associated features, with the 
possible exception of BMI and waist circumference, which tended to be higher in ApoA-1 IgG 
positive FH children than seronegative ones. Anti-ApoA-1 IgG positive subjects showed significantly 
lower median levels of LDL cholesterol, total cholesterol, and miR-33a, with a marginal trend for 
apoB particles when compared to anti-ApoA1 IgG negative subjects (Table 2). Significant correlations 
were only observed between anti-ApoA-1 IgG and miR-33a levels (r = 0.42, p = 0.02). 
In age-matched healthy children, the aforementioned differences between anti-ApoA-1 IgG 
seropositive and seronegative individuals related to lipid profile and miR-33a levels were not 
observed (Table 3). In contrasting to the observation in FH children, we observed that BMI, waist, 
and arm circumference in healthy children were lower in subjects positive for anti-ApoA-1 IgG when 
compared to seronegative children. 
Table 1. Baseline demographic and biological characteristics of subjects according to familial 
hypercholesterolemia (FH) status. 
Characteristic Healthy Children (n = 25) FH Children (n = 29) * p-Value 
Age, year (IQR) 8.5 (7–11) 9 (6–11) 0.89 
Sex (male %) 45 48.2 0.88 
BMI (kg/m2) 19 (16.6–20.2) 17.8 (15.6–20) 0.55 
Systolic BP *, mmHg (IQR) 105 (95–110) 110 (100–120) 0.14 
Diastolic BP, mmHg (IQR) 60 (60–70) 60 (60–70) 0.75 
Waist circumference, cm (IQR) 61.5 (53–69) 60 (53–68) 0.94 
Hip circumference, cm (IQR) 66 (61–76) 64 (57–73) 0.85 
Arm circumference, cm (IQR) 20 (18–22) 20 (17–23) 0.83 
Total cholesterol (mg/dL) 152.5 (138–167.5) 231 (213–280) <0.0001 
LDL cholesterol (mg/dL) 91.4 (79.5–103) 156 (137.6–211.6) <0.0001 
HDL cholesterol (mg/dL) 52 (43.5–58.5) 57 (51–66.5) 0.02 
Triglycerides (mg/dL) 56.5 (45.5–63) 64 (47–75) 0.17 
Apolipoprotein B (mg/dL) 65 (49–81.5) 93 (86–134) <0.0001 
Anti-ApoA-1 IgG (OD value) 0.53 (0.4–0.77) 0.55 (0.5–0.68) 1 
Anti-ApoA-1 IgG positivity (%) 38.8 37.9 0.9 
miR-33a (2^-ΔCt) 0.05 (0.03–0.2) 0.4 (0.19–1) <0.0001 
* p-values were obtained by comparing FH positive versus FH negative subjects, p-values were 
calculated using the Mann–Whitney U test. BMI, body mass index. BP, blood pressure. IQR: 
interquartile range. 
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Table 2. Baseline demographic and biological characteristics of FH children according to anti-ApoA-1 IgG status. 
Characteristic Healthy Children (n = 25) Anti-ApoA-1 Negative (n = 15) Anti-ApoA-1 Positive (n = 10) * p-Value 
Age, year (IQR) 8.5 (7–11) 10 (7–11) 7 (7–9) 0.08 
Sex (male %) 45 42.8 50 0.28 
BMI (kg/m2) 19 (16.6–20.2) 19.2 (17–20.2) 17.2 (15.4–19.5) 0.02 
Systolic BP *, mmHg (IQR) 105 (95–110) 100 (90–105) 110 (100–120) 0.7 
Diastolic BP, mmHg (IQR) 60 (60–70) 60 (60–75) 62.5 (60–70) 0.53 
Waist circumference, cm (IQR) 61.5 (53–69) 66 (51–69) 61 (54–64) 0.03 
Hip circumference, cm (IQR) 66 (61–76) 70 (61–76) 66 (61–67) 0.09 
Arm circumference, cm (IQR) 20 (18–22) 20 (17–22) 19.5 (18–21) 0.01 
Total cholesterol (mg/dL) 151 (138.5–167.5) 147 (135–167) 163 (148–168) 0.27 
LDL cholesterol (mg/dL) 91.4 (79.5–103) 89.4 (72–95) 101.8 (87–108) 0.11 
HDL cholesterol (mg/dL) 52 (43.5–58.5) 50.5 (39–55) 56 (47–62) 0.12 
Triglycerides (mg/dL) 56.5 (45.5–63) 58.5 (47–70) 55 (41–58) 0.97 
Apolipoprotein B (mg/dL) 65 (49–81.5) 53.5 (40–66) 79.5 (69–85) 0.19 
miR-33a  (2^-ΔCt) 0.05 (0.03–0.25) 0.1 (0.03–0.26) 0.05 (0.04–0.1) 0.4 
* p-values were obtained by comparing anti-ApoA-1 IgG positive versus anti-ApoA-1 IgG negative subjects, p-values were calculated using the Mann–Whitney U 
test. IQR: interquartile range. 
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Table 3. Baseline demographic and biological characteristics of healthy children according to anti-ApoA-1 IgG status. 
Characteristic FH Children (n = 29) Anti-ApoA-1 Negative (n = 18) Anti-ApoA-1 Positive (n = 11) * p-Value 
Age, year (IQR) 9 (6–11) 8 (7–10) 10 (6–13) 0.45 
Sex (male %) 48 54.5 72.7 0.08 
BMI (kg/m2) 17.8 (15.6–20) 16.8 (15.3–18.2) 19.3 (17.4–21.9) 0.05 
Systolic BP*, mmHg (IQR) 110 (100–120) 110 (100–115) 110 (100–125) 0.39 
Diastolic BP, mmHg (IQR) 60 (60–70) 62.5 (60–70) 60 (60–70) 0.58 
Waist circumference, cm (IQR) 60 (53–68) 56.5 (53–63) 66 (61–70) 0.05 
Hip circumference, cm (IQR) 64 (57–73) 72 (64–80) 62.5 (57–71) 0.10 
Arm circumference, cm (IQR) 20 (17–23) 22 (22–23) 19 (17–22) 0.14 
Total cholesterol (mg/dL) 213 (213–280) 263 (219–305) 209 (188–240) 0.04 
LDL cholesterol (mg/dL) 156.6 (137.6–211.6) 191.2 (144.6–228) 124.4 (113.8–168.8) 0.04 
HDL cholesterol (mg/dL) 57 (51–66.5) 61 (55–67) 55 (50–58) 0.24 
Triglycerides mg/dL) 64 (47–75) 60 (47–66) 66 (35–78) 0.35 
Apolipoprotein B (mg/dL) 93 (86–134) 109 (91–143) 86 (76–103) 0.05 
miR-33a (2^-Ct) 0.41(0.19–1.03) 0.85 (0.36–1.2) 0.28 (0.14–0.5) 0.04 
* p-values were obtained by comparing anti-ApoA-1 IgG positive versus anti-ApoA-1 IgG negative subjects, p-values were calculated using the Mann–Whitney U 
test. IQR: interquartile range. 
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3.2. Lower Level of miR-33a in Anti-ApoA-1 IgG-Treated Human Macrophages 
To further explore a possible causal link between the presence of anti-ApoA-1 antibodies, lower 
miR-33a levels, and a more favorable lipid profile in FH children, we first tested the ability of 
polyclonal anti-ApoA-1 IgG or control IgG to modulate the in vitro miR-33a production in human 
monocyte-derived macrophages (HMDM). 
After a time course of 4, 8, 16, and 24 h of antibody exposure, miR-33a levels were detected by 
quantitative PCR, as shown in Figure 1a. Anti-ApoA-1 IgG, and not control IgG, was found to 
decrease the miR-33a production in vitro on HMDM. As shown in Figure 1a, when compared to 
baseline conditions and control IgG, anti-ApoA-1 IgG (40 μg/mL) induced a slight but consistent 
decrease of cellular miR-33a levels during each time point, with the exception of 4 h stimulation, and 
was statistically significant at 24 hours (p < 0.01). As shown in Figure 1b, this anti-ApoA-1 IgG-
induced miR-33a downregulation was associated with a decreased miR-33a level at 24 h in the cell 
supernatant. Up to now, most of the anti-ApoA-1 IgG pro-atherogenic effects have been shown to be 
mediated by TLR2/TLR4/CD14 complex engagement followed by nuclear factor (NF)-kB and 
activator protein (AP)-1 pathway activation [4,14,17], and we examined the role TLR2/4, CD14, NF-
kB, and AP-1 in the anti-ApoA-1 IgG-mediated downregulation of miR-33a. Accordingly, we 
pretreated these cells with blocking antibodies against TLR2, TLR4, and the co-receptor CD14, and 
added chemical inhibitors BAY11-7082 (5 μM) or SP600125 (20 μM), specific to NF-kB and AP-1, 
respectively, 30 minutes before treatment with polyclonal anti-ApoA-1 IgG for 24 h. As shown in 
Figure 1c, none of the used inhibitors modulated the anti-ApoA-1 IgG effect on miR-33a, suggesting 
that the anti-ApoA-1 IgG-dependent miR-33a regulation was independent of TLR2/4/CD14 complex 
signaling. 
We then looked at the primary miR-33a (pri-miR-33a) precursor transcript that, after complex 
processing, gives the mature miR-33a, as well as at the SREBP2 mRNA, since miR-33a is located in 
the intronic region of SREBP2 gene [23,37] and we checked whether they would follow the same 
regulation as for miR-33a. Surprisingly, HMDM exposure to anti-ApoA-1 IgG for 24 hours 
significantly increased pri-miR-33a levels as well as SREBP2 mRNA (Figure 2a, b). 
These results suggest that despite the fact that the levels of primary miR-33a transcript are 
increased by anti-ApoA-1 IgG, the mature intracellular miR-33a form is nevertheless decreased by 
anti-ApoA-1 IgG exposure. Current ongoing investigations to dissect the exact mechanisms 
underlying this discrepancy indicate that miR-33a stability issues rather than maturation or nuclear 
export defects may be involved, but no clear-cut mechanisms have been identified so far. 
 
Figure 1. Lower levels of intracellular and extracellular miR-33a in anti-ApoA-1 IgG-treated human 
macrophage. Cells were treated with anti-ApoA-1 IgG or control antibodies for 4, 8, 16, and 24 h and 
RT-PCR was performed to determine (a) intracellular miR-33a levels as well as (b) miR-33a in the 
supernatant counterpart after 24 h anti-ApoA-1 IgG or control IgG treatment. (c) Blocking antibodies 
againstTLR2/4 were used as well as inhibitors of NF-kB and AP-1 to investigate the anti-ApoA-1 IgG 
mediated miR-33a downregulation. In (a,b), data are expressed as fold change expression of the mean 
± SD of miR-33a calculated by ΔΔCT method of five independent experiments (n = 5) and values were 
normalized to untreated condition, while in panel (c), data are expressed as miR-33a quantity (2−ΔΔCt). 
p-values were calculated using Student’s t-test. Panel a, * p = 0.015, ** p = 0.0012. Panel b, the difference 
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is not statistically significant, anti-ApoA-1 IgG vs. untreated p = 0.11, anti-ApoA-1 IgG vs. ctl control 
IgG p = 0.28. (c), ** p = 0.0017. 
 
Figure 2. Primary miR-33a and SREBP2 mRNA are upregulated by anti-ApoA-1 IgG. Cells were 
treated with anti-ApoA-1 IgG or control antibodies for 24 h and RT-PCR was performed to determine 
pri-miR-33a and SREBP2 mRNA levels (a,b). Data are expressed as fold change expression of the 
mean ± SD of pri-miR-33a or SREBP2 mRNA calculated by ΔΔCT method of five independent 
experiments (n = 5) and values were normalized to untreated condition. p-values were calculated 
using the Student’s t-test. (a), * p = 0.032, ** p = 0.0031; (b), * p = 0.043, ** p = 0.007. 
3.3. Anti-ApoA-1 IgGs Modulate Cholesterol-Regulating Proteins in Macrophages 
We further investigated the possible modulation, by anti-ApoA1 IgG, of SREBP2 transcription 
factor known to bind and activate LDL-R and HMGCR gene transcription [37–39] involved in 
cholesterol uptake and biosynthesis respectively. After 24 h of stimulation, anti-ApoA-1 IgG 
treatment increased the levels of SREBP2, HMGCR, and LDL-R protein when compared to the control 
IgG (Figure 3). As shown in Figure 3, only anti-ApoA-1 IgGs and not the control IgGs were found to 
increase the expression of the SCAP protein (SREBP cleavage-activating protein), responsible for 
cleaving and activating SREBP2 [40]. 
 
Figure 3. Anti-apoA-1 IgGs interfere with key regulators of cholesterol metabolism in macrophages. 
Anti-ApoA-1 IgGs induced the expression of the key regulators of the cholesterol pathway after 24 h 
as evidenced by Western blot. One of four representative Western blot is shown (n = 4). 
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3.4. The Impact of Anti-ApoA-1 IgG on Cholesterol-Regulating Proteins Is Mediated by TLR2 and TLR4 
Furthermore, we examined the role of TLR members as well as CD14, NF-kB, and AP-1 in the 
anti-ApoA-1 IgG-mediated upregulation of SREBP-2, LDL-R, and HMGCR on HMDM. Blocking both 
TLR2 and TLR4, NF-kB, and AP-1, as previously described, induced a significant reduction in the 
SREBP-2, LDL-R, and HMGCR protein expression (Figure 4b–d), while only blocking AP-1 
significantly decreased anti-ApoA-1 IgG-induced HMGCR protein expression (Figure 4d). 
 
Figure 4. The impact of anti-ApoA-1 IgG on cholesterol metabolism is mediated by TLR2, TLR4, Nf-
KB, and AP-1 transcription factors. Western blot-derived results showed that anti-ApoA-1 IgG-
mediated upregulation of SREBP2, LDL-R, and HMGCR on human monocyte-derived macrophages 
(HMDM) is significantly reduced by blocking TLR2 and TLR4 with specific blocking antibodies. 
Blocking NF-kB and AP-1 using the specific inhibitors BAY117082 and SP600125 respectively 
provided similar results. (a) One of five representative Western blots is shown. (b–d) Data are 
expressed as mean ± SD of band intensity volume/actin intensity volume from five different 
experiments (n = 5). p-values were calculated using the Student’s t-test: * p < 0.05, ** p < 0.01. 
3.5. Anti-ApoA-1 IgGs Promote LDL Uptake and Foam Cell Formation 
The complexity underlined by the previous observations indicating that i) anti-ApoA-1 IgG are 
associated with a more favorable lipid profile in FH children but lower miR-33a levels and ii) that 
these antibodies could increase both pro-atherogenic (HMGCR increase) and anti-atherogenic 
pathways (SREBP-2, LDLR) in vitro prompted us to evaluate the global result of exposing human 
macrophages to anti-ApoA-1 IgG in terms of foam cell formation. For this purpose, HMDM were 
treated with or without LDL (20 μg/mL) in the presence or absence of anti-ApoA-1 IgG (40 μg/mL) 
or control IgG (40 μg/mL) for 24 hours and followed by Oil Red O staining of HMDM. As shown in 
Figure 5, anti-ApoA-1 IgG exposure without LDL induced a modest but significant increase in 
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cellular lipid content when compared to control IgG (Figure 5b). Furthermore, in the presence of LDL, 
the effect of anti-ApoA-1 IgG was enhanced (Figure 5a, b). In presence of LDL, the anti-ApoA-1 IgG 
effect on foam cell formation was abrogated by all the inhibitors used, with the exception of AP-1 
inhibitor, which nevertheless provided a close to significant inhibition (Figure 5b). Taken together, 
these results indicate that anti-ApoA-1 IgG promotes foam cell formation through partly TLR2/4-
dependent pathways. Of note, this anti-ApoA-1 IgG-induced foam cell formation was specifically 
enhanced by native LDL because in presence of oxidized LDL, anti-ApoA-1 IgG increases foam cell 
formation to the same extent as anti-ApoA-1 IgG alone (Supplemental Figure S1). 
Importantly, given the fact that LDL per se substantially induced foam cell formation regardless 
of the concomitant presence of anti-ApoA-1 IgG, the rest of our experimental procedures were carried 
out without LDL in order to assess the effects specifically ascribed to anti-ApoA-1 IgGs. 
 
Figure 5. Anti-ApoA-1 IgG promote LDL uptake and foam cell formation mediated by TLR2/4, NF-
kB, and AP1. (a) HMDM were treated for 24 h with anti-ApoA-1 IgG or ctl IgG in the presence or 
absence of native LDL (20 μg/mL). Cells were stained with Oil Red O to highlight the lipid uptake. 
(b) Blocking antibodies to TLR2/4 were used as well as inhibitors to NF-kB and AP-1 to try to inhibit 
the anti-ApoA-1 IgG mediated LDL uptake as evidenced by Oil Red O staining quantification as the 
mean granule area per cell. Oil Red O was quantified as indicated in the method section. Results are 
expressed in arbitrary units as mean ± SD of four independent experiments (n = 4), p-values were 
calculated using the Student’s t-test: ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
3.6. Anti-ApoA-1 IgGs Upregulate ABCA1 
Because ABCA1 is a known target of miR-33a [23], we expected that the anti-ApoA-1 IgG-induced 
downregulation of miR-33a would increase ABCA1 expression. As shown in Figure 6, anti-ApoA-1 IgG 
increased both the mRNA (Figure 6a) and protein levels of ABCA1 (Figure 6b) in HMDM. 
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Figure 6. Anti-ApoA-1 IgGs upregulate ABCA1. ABCA1 was increased after 16 and 24 h of anti-
ApoA-1 IgG exposure to HMDM at the mRNA level as revealed by RT-PCR (a) as well as at the 
protein level after 24 h anti-apoA-1 IgG stimulation, as revealed by Western blot analysis (b). In panel 
a, data are expressed as fold change expression of the mean ± SD of ABCA1 calculated by ΔΔCT 
method of six independent experiments (n = 6) and values were normalized to untreated condition. 
p-values were calculated using the Student’s t-test: * p < 0.05, ** p < 0.01, **** p < 0.0001. (b) One of four 
representative Western blots is shown. Data are the mean ± SD of band intensity volume/actin 
intensity volume of four independent experiments (n = 4). p-values were calculated using the 
Student’s t-test: * p = 0.02, ** p = 0.005. 
3.7. ACAT Activity and Cellular Cholesterol Distribution in Macrophages Following Anti-ApoA1 IgG Treatment 
Because ABCA1 levels are known to be upregulated as part of a homeostatic feedback loop in 
presence of intracellular lipid overload [36], the previous experiments did not allow us to conclude 
whether there was a direct or indirect effect of anti-ApoA-1 IgG on ABCA1 levels. Nevertheless, as the net 
effect of anti-ApoA-1 IgGs was an increase in foam cell formation (which is usually associated with lower 
ABCA1 levels), we primarily suspected that the ABCA1 increase in response to anti-ApoA-1 IgG was part 
of a negative feedback mechanism. In that case, the exposure of anti-ApoA-1 IgG on HMDM should 
primarily reorient the free cholesterol present in the plasmatic membrane toward esterified cholesterol 
intracellular pools, which is mediated by the acyl coenzyme A: cholesterol acyltransferase (ACAT) [41]. 
To validate this hypothesis, we assessed the impact of anti-ApoA-1 IgGs on the ACAT activity and protein 
levels on HMDM. As shown in Figure 7a, anti-ApoA-1 IgGs increased ACAT activity, while the protein 
levels remained unchanged (Supplemental Figure S2). 
As shown in Figure 7b, this anti-ApoA-1 IgG- induced ACAT activation was accompanied by a 
significant reduction of free cholesterol content in membrane and a non-significant reduction of the 
free cholesterol content in the cell supernatant counterpart (Figure 7c). 
 
Figure 7. Effect of anti-ApoA-1 IgG on cholesterol distribution. (a) Cells were incubated for 24 hours 
in RPMI medium with 10% FCS, control IgGs, or anti-ApoA-1 IgG. Monolayers underwent a second 
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incubation (4 h) in the presence of [1-14C]-oleic acid albumin complex. Data are expressed as the mean 
± SD of the measurements done in triplicate and repeated on three HMDM donors (n = 3). Statistical 
differences were determined by Student’s t-test: ** p ≤ 0.0036. (b) HMDM were labelled with 3 μCi/mL 
[3H] cholesterol for 24 h in RPMI medium with 10% FCS, control IgGs or anti-ApoA-1 IgGs. Cells 
were then washed and incubated with 1 U/mL cholesterol oxidase enzyme in DPBS for 4 hours at 37 
°C. Data are expressed as the mean ± SD of the measurements done in triplicate and repeated on three 
HMDM donors (n = 3), p-values were calculated using the Student’s t-test: * p < 0.05. (c) Free 
cholesterol content in HMDM supernatant after exposure of cells to anti-ApoA-1 IgGs or control IgGs 
was expressed as μg of free cholesterol per well. Data are expressed as the mean ± SD of the 
measurements done on five HMDM donors (n = 6). The differences between groups were not 
statistically significant, anti-ApoA-1 IgG vs. untreated p = 0.12; anti-ApoA-1 IgG vs. ctl IgG p = 0.14. 
3.8. Anti-ApoA-1 IgG Impact on Cholesterol Passive Diffusion 
Cholesterol passive diffusion (also known as aqueous diffusion) represents the free cholesterol 
exchange occurring between cells membranes and plasma by a passive process driven by free 
cholesterol concentration gradients towards HDL/ApoA-1, independently of any efflux pumps [36] 
In normocholesterolemic conditions, passive diffusion has been shown to account for up to 80% total 
cholesterol macrophage efflux [42]. Given the decrease in membrane free cholesterol induced by anti-
ApoA-1 IgG in response to the ACAT redistribution within intracellular pools, we expected these 
antibodies to decrease passive diffusion due to the decrease in the free cholesterol gradient. For this 
purpose, we used a validated model of human macrophage derived from THP-1 monocytic cell line 
[35] as our human primary macrophage model was not validated for such kind of experiments. Cells 
were treated for 24 h with anti-ApoA 1 IgGs or control IgGs in the absence of serum but in presence 
of 0.2% albumin to avoid any active ABCA1-, ABCG1- or SR-B1-mediated cholesterol efflux. As 
shown in Figure 8, anti-ApoA-1 IgGs significantly decreased the passive diffusion. 
 
Figure 8. Anti-ApoA-1 IgGs inhibit passive diffusion. THP-1 cells were treated for 24 h with anti-
ApoA-1 IgGs or ctl IgGs and passive diffusion was analyzed and expressed as percentage of the 
radioactivity released to the medium in 4 h over the total radioactivity incorporated by cells. p-values 
were calculated using the Student’s t-test: ** p = 0.010, *** p < 0.001. 
4. Discussion 
In this study, we report, for the first time, that the prevalence of high anti-ApoA-1 IgG levels in 
children devoid of any concomitant autoimmune diseases is substantial, reaching 38%, and seemed 
unrelated to familial hypercholesterolemia. Such a prevalence is similar to what has been reported in 
adults in secondary prevention or equivalent CV risk-associated conditions [4,7,43], and close to 
double of what has been observed in a general adult population [3], where these antibodies were 
shown to be associated with a worse overall and CV prognosis [3,5]. 
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The second notable finding of this study is that FH positive children with high anti-ApoA-1 IgG 
levels displayed a more favorable lipid profile consisting of lower total and LDL cholesterol levels, when 
compared to children who tested negative for these autoantibodies. These results complement previous 
observations [3,13,15,16] showing that high anti-ApoA-1 IgG levels were associated with lower total, LDL, 
and miR-33a levels, despite being associated with increased CVD risk, according to previous reports 
[3,13,15,16]. This clinical observation derived from a limited number of pediatric FH patients (and not 
retrieved on age and gender matched controls), prompted us to evaluate the ability of anti-ApoA-1 IgG 
to promote in vitro foam cell development on human primary macrophages, and to determine the 
molecular mechanisms involved, which led to the following new mechanistic findings. 
If the role of the TLR2/4/CD14 complex has been well documented accounting for the cytokine-
dependent pro-inflammatory, pro-thrombotic, and pro-arrythmogenic biological properties ascribed 
to anti-ApoA-1 IgG [9,14,17], this is the first demonstration that these antibodies promote foam cell 
formation on human macrophages by the same innate immune receptors. Our results demonstrate 
that anti-ApoA-1 IgGs upregulate the expression of key cholesterol homeostasis-related proteins, 
such as SREBP2, LDL-R, and HMGCR in a TLR2/4 complex-dependent manner, leading to both 
increased LDL uptake and intracellular cholesterol synthesis, independently of oxidized LDL uptake. 
We considered this cellular cholesterol overload as the key driver of ACAT stimulation [44] leading 
to the esterification of free cholesterol excess into intracellular cholesterol pools (lipid droplet 
accumulation) and decreased the amount of plasma membrane free cholesterol, diminishing the free 
cholesterol gradient requested for passive diffusion, a key macrophage cholesterol efflux regulator 
in normolipidemic conditions [36]. Our observations are in line with previous observations 
demonstrating that TLR4 and TLR2 agonists can upregulate SREBP2, HMGCR, and LDL-R 
expression and promote foam cell formation independently of oxidized-LDL uptake [29,45,46]. 
In this context, the anti-ApoA-1 IgG-induced increase of the anti-atherogenic ABCA1 protein 
expression, and decrease in pro-atherogenic miR-33a has to be understood as the reflection of the 
activation of a compensatory but insufficient homeostatic feedback loop to limit intracellular cholesterol 
overload for two main reasons. First of all, our results indicate that miR-33a expression is independent of 
TLR2/TLR4 signaling, whereas TLR2 and 4 ligands have been reported to downregulate miR-33a in the 
case of direct signaling [47]. Secondly, any increase in intracellular cholesterol accumulation is known to 
downregulate miR-33a expression which, in turn, will alleviate miR-33a-mediated ABCA1 inhibition, 
leading to an increase in ABCA1 protein expression and ABCA1 efflux independently of TLR stimulation 
[23,48]. Taken together, these results indicate that in our experimental context, changes in miR-33a and 
ABCA1 expression have to be considered as the effectors of a negative feedback loop aimed at limiting 
anti-ApoA-1 IgG-induced intracellular lipid accumulation without being able to fully prevent it, as a 
common feature of negative feedback loops [49]. Nevertheless, our results indicate that in presence of anti-
ApoA-1 IgG, the usual negative feedback mechanism activated by high intracellular cholesterol levels to 
reduce LDLR seems to be blunted [49]. The exact mechanisms underlying this observation are currently 
unknown and warrant further investigations. 
Despite these remaining questions, to the best of our knowledge, this is the first thorough 
experimental demonstration unravelling the detailed mechanisms by which anti-ApoA-1 IgGs could 
promote atherogenesis by acting as disruptors of macrophage cholesterol homeostasis by increasing 
both LDL uptake and intracellular cholesterol synthesis independently of oxidized LDL. As such, our 
results show that anti-ApoA-1 IgGs have at least two antagonist mechanisms of action to those of 
statins in the sense that the former act as HMGCR and ACAT activators, whereas statins act as 
HMGCR and ACAT inhibitors [50] Although, concordant with our clinical data, knowing whether 
these mechanisms could explain the clinical associations retrieved between anti-ApoA-1 IgG and 
lipid profile remains to be determined. Our current understanding of these possible 
pathophysiological mechanism is summarized in Supplemental Figure S3. 
This study has several limitations. It is worth mentioning the very limited size of our FH 
pediatric sample used in this translational study, due to the low prevalence of FH [51] and the issues 
related to pediatric blood sampling. Despite this power limitation, the significant associations 
derived from this cohort were instrumental in providing guidance for the in vitro experiments which, 
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in turn, provided results that could explain the reported clinical associations, albeit not providing a 
formal demonstration. Another limitation resides in the unresolved paradox raised by the fact that 
anti-ApoA-1 IgG can decrease mature miR-33a levels despite increasing levels of miR-33a precursor. 
The reason underlying such an observation is under active investigation, as we currently suspect a 
possible effect of anti-ApoA-1 IgG on miRNA decay that we did not investigate due to highly elusive 
mechanisms underlying miRNA stability [52,53], which could not be resolved within the scope of the 
present work. The third limitation is that we did not consider ABCA1 efflux in this work because all 
our experiments related to protein regulation were done in normocholesterolemic conditions without 
additional LDL, where passive diffusion is believed the main functional driver of the cholesterol 
efflux in macrophages [36]. Nevertheless, as ABCA1 levels were increased in response to anti-ApoA-
1 IgG as part of the negative feedback loop (see above), we expect ABCA1 cholesterol efflux to be 
concomitantly increased, but not sufficiently to inhibit anti-ApoA-1 IgG-induced foam cell formation. 
Lastly, due to limited human sample availability, we could not evaluate the effect of human purified 
anti-ApoA-1 IgG in this study. Nevertheless, as we previously demonstrated that the commercial 
anti-human ApoA-1 IgG used in this study promoted the same effects as the human-purified IgG 
fraction containing high levels of these autoantibodies in vitro [9,17], and because these 
autoantibodies have been consistently used in different validated and published animal and in vitro 
studies [9,12–14,17], we expect a similar impact on in vitro lipid metabolism to occur by using human 
purified anti-ApoA-1 IgG, even if not formally demonstrated. 
In conclusion, the results of this hypothesis-generating translational study show that the 
prevalence of ApoA-1 IgG seropositivity is frequent in children, unrelated to FH, and surprisingly 
associated with a favorable lipid profile in FH but not in controls. Furthermore, anti-ApoA-1 IgG 
were found to induce foam cell formation in vitro through a complex interplay between innate 
immune receptors and key cholesterol homeostasis regulators, functionally impairing the cholesterol 
efflux capacity of macrophages. The clinical implications of these findings are unclear, but may 
suggest that the presence of circulating anti-ApoA-1 IgG could not only interfere with some beneficial 
effects of lipid-lowering drugs in humans, but could also potentially decrease the contribution of the 
lipid profile to the individual’s CV risk in current CV risk stratification tools. If so, these antibodies 
may be considered as an additional CV risk enhancer to the list of the factors already considered as 
such in the latest dyslipidemia management guidelines [54]. These hypotheses are currently devoid 
of any experimental evidence and await further investigations. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1, Figure S1: Anti-ApoA-
1 IgGs don’t promote oxLDL uptake, Figure S2: ACAT-1 expression is not modulated by anti-ApoA-1 IgG, 
Figure S3: Summary of the anti-ApoA-1 IgG-mediated foam cell formation. 
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